Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Esther Yoon

Family Medicine Glendale, CA Medical Doctor

NPI 1174725683 CMS profile 234705

1901 Broadview Dr, Glendale, CA 91208

Open in the dashboard

General payments

$4,288

160 records reported · program years 2019–2025

Research payments

$10,790

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,775,062 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Esther Yoon of Glendale, CA is reported in the CMS Open Payments database as having received $4,288 across 160 general payments and $10,790 in research payments paid to them. Separately, studies naming them as principal investigator received $5,775,062 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $405 12
2024 General $807 32
2023 General $617 25
2023 Research $3,715 1
2022 General $930 32
2022 Research $7,075 1
2021 General $640 31
2020 General $349 16
2019 General $542 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esther Yoon
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Esther Yoon were reported at $405. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Esther Yoon Family Medicine median Middle half National median
2019 $542 $150 $41–$543 $163
2020 $349 $120 $32–$415 $114
2021 $640 $137 $35–$551 $132
2022 $930 $137 $37–$512 $149
2023 $617 $149 $42–$545 $160
2024 $807 $156 $44–$560 $164
2025 $405 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,166 43 payments
  2. Abbott Laboratories $926 41 payments
  3. AbbVie, Inc. $748 30 payments
  4. Relievant Medsystems, Inc. $275 1 payment
  5. GlaxoSmithKline, LLC. $275 12 payments
  6. Amgen Inc. $132 5 payments
  7. Mannkind Corporation $125 1 payment
  8. Allergan Inc. $106 5 payments
  9. Biohaven Pharmaceuticals, Inc. $101 4 payments
  10. Amarin Pharma Inc. $84 4 payments
  11. Other $349 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,012 159 payments
  2. Travel and Lodging $275 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $672 34 payments
  2. RYBELSUS $654 33 payments
  3. FreeStyle Libre 2 $412 23 payments
  4. FreeStyle Libre 3 $390 17 payments
  5. CREON $300 14 payments
  6. Intracept Pain $275 1 payment
  7. Intracept Pain $275 1 payment
  8. TRELEGY ELLIPTA $275 12 payments
  9. Tresiba $271 8 payments
  10. UBRELVY $176 7 payments
  11. Other $1,635 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $10,790 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

1,783

Median for Family Practice: 1,826

Drug cost

$187,322

Median for Family Practice: $120,094

Branded share of claims

15.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 43 $50,309
Jardiance Empagliflozin Brand 17 $28,013
Prolia Denosumab Brand 14 $23,180
Eliquis Apixaban Brand 19 $20,452
Januvia Sitagliptin Phosphate Brand 12 $17,664
Vascepa Icosapent Ethyl Brand 18 $9,125
Tresiba Flextouch U-200 Insulin Degludec Brand 13 $8,233
Linzess Linaclotide Brand 12 $7,432
Icosapent Ethyl Generic 23 $2,414
Rosuvastatin Calcium Generic 144 $2,126

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$56,774

Of which drugs: $2,702

Medicare patients

134

Average age 75

Services billed

842

104 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 24%
Depression 23%
Ischemic heart disease 21%
Cancer 20%
Chronic kidney disease 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 21 21 $1,646

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $74
$74 — —
RYBELSUS
  • Novo Nordisk Inc $50
$50 — —
Ozempic
  • Novo Nordisk Inc $50
$50 43 —
LINZESS
  • AbbVie, Inc. $23
$23 12 —
CREON
  • AbbVie, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record